HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MySpace Too, Says P&G; Social Media Butterfly Creating Buzz Online

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble is blazing the trail for beauty companies across social networking Web sites like MySpace and YouTube, connecting with consumers on a new level and promoting its brands virally

You may also be interested in...



Social Media Marketing, Product Innovation Crucial As Economy Improves

With the market showing signs of recovery, personal-care companies should be certain not to skimp on innovation, at minimum taking advantage of "entirely affordable" opportunities for marketing through social media, according to a report from Kline & Co.'s Carrie Mellage

Social Media Marketing, Product Innovation Crucial As Economy Improves

With the market showing signs of recovery, personal-care companies should be certain not to skimp on innovation, at minimum taking advantage of "entirely affordable" opportunities for marketing through social media, according to a report from Kline & Co.'s Carrie Mellage

Along With Marketing Gains, Social Media Bring Possible Problems

Social media sites like Facebook and Twitter are emerging as invaluable marketing resources for medical device and drug companies, but as FDA develops guidance on the issue companies should be careful to control the content of their Web postings, marketing experts caution

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel